Mesoblast Ltd Files 6-K Report

Ticker: MEOBF · Form: 6-K · Filed: Jul 2, 2024 · CIK: 1345099

Mesoblast LTD 6-K Filing Summary
FieldDetail
CompanyMesoblast LTD (MEOBF)
Form Type6-K
Filed DateJul 2, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: filing, foreign-private-issuer, regulatory-update

TL;DR

MESO filed a 6-K with SEC on July 1st, standard foreign issuer update.

AI Summary

On July 1, 2024, Mesoblast Limited filed a new release announcement with the Australian Securities Exchange. This report is a Form 6-K filing with the SEC, indicating it's a report from a foreign private issuer for the month of July 2024. The company is incorporated in Australia and its principal executive offices are located in Melbourne.

Why It Matters

This filing serves as an update for investors regarding Mesoblast Limited's regulatory and corporate activities as a foreign private issuer.

Risk Assessment

Risk Level: low — This filing is a routine report for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

This Form 6-K filing is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of July 2024.

When did Mesoblast Limited file its announcement with the Australian Securities Exchange?

Mesoblast Limited filed a new release announcement with the Australian Securities Exchange on July 1, 2024.

Where are Mesoblast Limited's principal executive offices located?

Mesoblast Limited's principal executive offices are located at Level 38, 55 Collins Street, Melbourne 3000, Australia.

Who is the Chief Executive Officer and Executive Director of Mesoblast Limited?

Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.

Does Mesoblast Limited file annual reports under Form 20-F or Form 40-F?

Mesoblast Limited files annual reports under Form 20-F.

Filing Stats: 213 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-07-01 19:28:35

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Paul Hughes Paul Hughes Company Secretary Dated July 2, 2024 INDEX TO EXHIBITS Item 99.1 Press release of Mesoblast Ltd, dated July 1, 2024 .

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing